Drug manufacturer Bayer has made public plans to launch new studies as a step toward seeking approval of its anticoagulant Xarelto for additional uses.
Rockville Centre, NY -- (SBWIRE) -- 08/29/2014 -- According to a Reuters report, Xarelto manufacturer Bayer is going to be testing the drug—currently very popular as a treatment for preventing strokes—on patients with “embolic stroke of undetermined source and peripheral artery disease” and for long-term prevention in patients who have suffered an acute coronary syndrome.”*
“This is troubling,” said Rochelle Rottenstein, principal of the Rottenstein Law Group. “The dangers of Xarelto are becoming clearer with each new complaint filed with the FDA and each new lawsuit filed against Bayer. To learn that Bayer is seeking to expand the uses of the embattled drug is disheartening.”
In 2013, the U.S. FDA received several hundred adverse event reports submitted by individuals who claimed to have a serious adverse side effect while taking Xarelto (rivaroxaban), as compared to a lower number for Pradaxa (dabigatran).** Data show that the number of persons being prescribed these blood thinning drugs is estimated at about 4 million for the year, with Xarelto prescriptions outnumbering Pradaxa prescriptions by two-to-one.** Anticoagulants (or “blood thinners”) are considered high-risk prescription drugs because they can cause excessive internal bleeding and other injuries in some patients.
Anyone needing more information about the dangers of Xarelto should visit http://www.rotlaw.com/xarelto/. Representatives of the Rottenstein Law Group are available to answer any questions, and there is a confidential, no-cost claim evaluation form at the site that can be filled out in order to determine if one has grounds to file a Xarelto lawsuit.
*http://www.reuters.com/article/2014/08/29/bayer-xarelto-idUSF9N0NY07P20140829
**http://www.ismp.org/quarterwatch/pdfs/2013Q1.pdf
ABOUT THE ROTTENSTEIN LAW GROUP LLP
The Rottenstein Law Group LLP is a New York-based firm that represents clients nationwide in mass tort actions. The firm was founded by Rochelle Rottenstein, who has more than two decades of experience as a lawyer, to represent clients hurt by defective medical devices and medications. (Attorney advertising. Prior results do not guarantee a similar outcome.)
Contact:
The Rottenstein Law Group LLP
Rochelle Rottenstein, Esq.
100 Merrick Road
Suite 226W
Rockville Centre, NY 11570
(212) 933-9500 (office phone)
(212) 933-9980 (facsimile)
rochelle (at) rotlaw (dot) com